HOME >> BIOLOGY >> NEWS
The PSA bounce Does it have clinical significance?

Using the largest known prostate cancer data set of patients treated solely with external-beam radiation in the U.S., radiation oncologists have examined the "PSA bounce" phenomenon and determined that it is not an indicator that men will die of prostate cancer any sooner than those men who do not experience a bounce. That is the result of a multi-institutional analysis presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

The PSA (prostate-specific antigen) test is a blood test used for routine prostate cancer screening. The "PSA bounce" is a rise and then decline in the PSA level following radiation treatment for prostate cancer. The bounce phenomenon occurs in a third to half of men treated with radiation for prostate cancer. Urologists, radiation and medical oncologists have struggled with what a bouncing PSA means for a patient's prognosis, and how or if to offer further treatment.

"Because a steady rise in PSA can mean that cancer has recurred, physicians often interpret a bounce as the possibility that the cancer may still exist after treatment," explained Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center and lead author of the study. "Some physicians prescribe hormonal therapy in this situation, but hormones can have significant side effects for the patient, and may not be clinically necessary. For these reasons, it's important to develop clear guidelines."

In this retrospective analysis, data were gathered from the records of 4,839 men treated only with external-beam radiation between 1986 and 1995 at nine institutions throughout the US. The median follow-up was 6.3 years. Treatment during this time period consisted primarily of conventional radiation therapy, a lower dose than is generally used at academic cancer centers today, although some patients were treated with 3D conformal radiation therapy. In thi
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
6-Oct-2004


Page: 1 2

Related biology news :

1. HIV-1 kills immune cells in the gut that may never bounce back
2. Phytoplankton bounce back from abrupt climate change
3. Fat kids can bounce back to normal blood pressure
4. Preclinical study links gene to brain aneurysm formation
5. Gene variant is associated with brain anatomy, clinical course of ADHD
6. New joint replacement material developed at MGH put to first clinical use
7. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
8. From clinical cancer research: rethinking therapeutic cancer vaccine trials
9. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
10. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
11. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
(Date:12/2/2016)... ... 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing the ... chain-of-custody solution for tracking and securing medications at booth 676 at the ASHP ... Aerocom has a proven solution for tracking medications via its system from pharmacy ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has ... three days and will take place on February 1-3, 2017 at the Roosevelt Hotel ... Gulley (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... client Nanowear on their recent FDA Class II 510(k) clearance for their flagship ... hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While ...
Breaking Biology Technology:
Cached News: